Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.48 |
| ▸ | CCR8 | P51685 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | ALPI | P09923 | 1/20 | 0.37 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9146011 | 0.97 | CCR1 (0.46) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL3417679 | 0.89 | CCR1 (0.40) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL30266840 | 0.87 | CCR1 (0.64) | CCR1CCR8SMN1; SMN2KCNH2NOS1 | |
| SCHEMBL8908397 | 0.87 | CCR1 (0.64) | CCR1CCR8SMN1; SMN2KCNH2NOS1 | |
| SCHEMBL245158 | 0.86 | CCR1 (0.55) | CCR1TDP1LMNASMN1; SMN2KCNH2 | |
| SCHEMBL313802 | 0.85 | KDM4E (0.63) | CCR1CCR8KDM4ETDP1L3MBTL1 | |
| SCHEMBL4435179 | 0.84 | MEN1 (0.60) | CCR1L3MBTL1HSP90AA1SMN1; SMN2KCNH2 | |
| SCHEMBL9355728 | 0.84 | CCR1 (0.36) | CCR1CCR8 | |
| Bromide SCHEMBL1259355 | 0.83 | CCR1 (0.52) | CCR1TDP1LMNASMN1; SMN2KCNH2 | |
| SCHEMBL15341667 | 0.82 | DYRK1A (0.40) | CCR1CCR8TP53SMN1; SMN2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665744-B1 | MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION | UNIV ROCHESTER (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2665744-B1 | MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION | UNIV ROCHESTER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8986953-B2 | Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation | UNIVERSITY OF ROCHESTER (US) | 2015-03-24 | — | — | US | disclosed |
| US-8986953-B2 | Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation | UNIVERSITY OF ROCHESTER (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130330773-A1 | MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION | NATIONAL SCIENCE FOUNDATION | 2013-12-12 | — | — | US | disclosed |
| EP-2665744-A2 | MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION | UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8586613-B2 | Pyridinium and quinolinium derivatives | UNIVERSIDAD DE GRANADA (ES) | 2013-11-19 | — | — | US | disclosed |
| WO-2013042120-A2 | SYNTHETIC UBIQUITINS AND USE THEREOF IN DRUG SCREENING ASSAYS | PROTEOLOGICS LTD (IL) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013042120-A2 | SYNTHETIC UBIQUITINS AND USE THEREOF IN DRUG SCREENING ASSAYS | PROTEOLOGICS LTD (IL) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012100176-A2 | MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION | UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-08-09 | — | — | US | disclosed |
| EP-1710236-A1 | DERIVATIVES OF PYRIDINE AND QUINOLINE | CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2006-10-11 | — | — | EP | disclosed |
| EP-0601113-B1 | RARE EARTH MACROCYCLIC COMPLEXES AND USE THEREOF FOR REDUCTION OF DISTURBANCES IN AN ASSAY USING FLUORESCENCE | CIS BIO INT (FR) | 1997-01-08 | — | — | EP | disclosed |
| US-5457184-A | Medical diagnosis | CIS BIO INTERNATIONAL (FR) | 1995-10-10 | — | — | US | disclosed |
| US-5432101-A | Complex consists of biologically active molecule associated by coupling or adsorption with the complex | COMPAGNIE ORIS INDUSTRIE SA (FR) | 1995-07-11 | — | — | US | disclosed |
| US-5220012-A | Macropolycyclic rare earth complexes and application as fluorescent tracers | COMPAGNIE ORIS INDUSTRIE SA (FR) | 1993-06-15 | — | — | US | disclosed |
| EP-0180492-B1 | MACROPOLYCYCLIC COMPLEXES OF RARE EARTH METALS AND APPLICATION AS FLUORESCENT LABELS | CIS BIO INTERNATIONAL (FR) | 1993-06-02 | — | — | EP | disclosed |
| WO-1993005049-A1 | RARE EARTH MACROCYCLIC COMPLEXES AND USE THEREOF FOR REDUCTION OF DISTURBANCES IN AN ASSAY USING FLUORESCENCE | CIS BIO INTERNATIONAL (FR) | 1993-03-18 | — | — | WO | disclosed |
| US-4927923-A | IMMUNOLOGY | COMPAGNIE ORIS INDUSTRIES (FR) | 1990-05-22 | — | — | US | disclosed |
| EP-0180492-A1 | Macropolycyclic complexes of rare earth metals and application as fluorescent labels | CIS BIO INTERNATIONAL (FR) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185170-A1 | Derivatives of pyridine and quinoline | CHKA, CHKB, PHOSPHO1 | CCR1 1569/4885CCR8 4258/4885KDM4E 499/4885 |
| US-20130330773-A1 | MACROCYCLIC COMPOUNDS WITH A HYBRID PEPTIDIC/NON-PEPTIDIC BACKBONE AND METHODS FOR THEIR PREPARATION | MICA, VIP, NPEPPS | CCR1 1077/4885CCR8 710/4885KDM4E 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.